Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

PURPOSE: Lenalidomide and rituximab (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed in randomized studies. PATIENTS AND METHODS: The Cancer and Leukemia Group B (Alliance) 50401 trial is a randomized phase II trial studying rituximab (375 mg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Leonard, John P., Jung, Sin-Ho, Johnson, Jeffrey, Pitcher, Brandelyn N., Bartlett, Nancy L., Blum, Kristie A., Czuczman, Myron, Giguere, Jeffrey K., Cheson, Bruce D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2015
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622102/
https://ncbi.nlm.nih.gov/pubmed/26304886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.9258
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge